Phase 3 study for people with Lymphoma
Recruiting Phase 3
This trial at a glance
Where this trial is running
| Site | City | State or country | Status at this site |
|---|---|---|---|
| Research Site | Clayton | VIC | Not yet recruiting |
| Research Site | Macquarie University | NSW | Withdrawn |
| Research Site | Melbourne | VIC | Recruiting |
| Research Site | Nedlands | WA | Not yet recruiting |
| Research Site | Waratah | NSW | Not yet recruiting |
voxsanity.com.au · trial sites from public registries · registry record synced 15 October 2026 · not medical advice
Who can join
The official eligibility criteria
Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.
Inclusion criteria:
* Participants are either 80 years of age or older, OR 65 to 79 years of age or older and classified as unfit per sGA, and otherwise not considered candidates for full-dose R-CHOP per investigator assessment;
* Histologically confirmed diagnosis of previously untreated LBCL as per WHO-HEM5 (excluding plasmablastic lymphoma) and follicular large cell lymphoma;
* FDG-avid and measurable disease as per Lugano and Ann Arbor staging;
* Stage I bulky (7.5 cm and greater) to Stage IV;
* ECOG performance status 0 to 2;
* Adequate bone marrow, liver, renal and cardiac function.
The above is a summary, other inclusion criteria details may apply.
* As judged by the investigator, any evidence of diseases which make it undesirable for the participant to participate in the study, or that would jeopardise compliance with the protocol
* Diagnosis of post-transplant lymphoproliferative disease, plasmablastic lymphoma, Richter's transformation, prior history of or concurrent indolent lymphoma (including de novo transformed or composite lymphoma).
* History of CNS involvement by their B-NHL or history of clinically relevant CNS medical condition
* Known history of hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS).
* Active or uncontrolled infection
* Major cardiac abnormalities
* Prior anti-lymphoma therapy except for corticosteroids for symptom control
* Requires chronic immunosuppressive therapy for active autoimmune/inflammatory condition, with some exceptions
The above is a summary, other exclusion criteria details may apply.
Dates on the record
Results, publications and the official record
- No results are posted on the official record yet.
- No publications are listed on the official record yet.
- Official record and contacts on ClinicalTrials.gov – contact details for each site are kept there, and are not copied onto this page.
Sources and dates
- ClinicalTrials.gov – the record this page reformats
- ClinicalTrials.gov processing date: 9 October 2026.
- This page last checked by Voxsanity: 15 October 2026.
Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.
Not medical advice.
Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.
Letter for your doctor
A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.